JP2014530010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530010A5 JP2014530010A5 JP2014533316A JP2014533316A JP2014530010A5 JP 2014530010 A5 JP2014530010 A5 JP 2014530010A5 JP 2014533316 A JP2014533316 A JP 2014533316A JP 2014533316 A JP2014533316 A JP 2014533316A JP 2014530010 A5 JP2014530010 A5 JP 2014530010A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- protein
- arginine
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725643 Respiratory syncytial virus Species 0.000 claims 26
- 108060003023 F Proteins 0.000 claims 17
- 239000004475 Arginine Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090001126 FURIN Proteins 0.000 claims 4
- 102000004961 Furin Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000000875 corresponding Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 210000004072 Lung Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108091006011 G proteins Proteins 0.000 claims 1
- 102000030007 GTP-Binding Proteins Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins Proteins 0.000 claims 1
- 101700062818 NP Proteins 0.000 claims 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 1
- 101700055524 VME1 Proteins 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 101700045377 mvp1 Proteins 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Claims (10)
- 哺乳動物の肺において呼吸器合胞体ウイルス（ＲＳＶ）の複製を予防する方法において使用するための、ＲＳＶ融合（Ｆ）タンパク質であって、
前記ＲＳＶ Ｆタンパク質が：
（ｉ）野生型ＲＳＶ Ｆタンパク質（配列番号２）のアミノ酸の約１３７〜１４６位に対応する融合ドメインのＮ末端半分における欠失と、
（ｉｉ）不活性化した一次フューリン切断部位であって、前記一次フューリン切断部位が野生型ＲＳＶ Ｆタンパク質（配列番号２）の１３１〜１３６位のアミノ酸に対応し、野生型ＲＳＶ Ｆタンパク質（配列番号２）のアルギニン１３３、アルギニン１３５およびアルギニン１３６からなる群から選択されるアミノ酸に対応する位置に少なくとも１つのアミノ酸置換を含む不活性化した一次フューリン切断部位と、
を含み、
前記使用が、約５μｇ〜約６０μｇの範囲のタンパク質投与量で哺乳動物にＲＳＶ Ｆタンパク質を投与することを含み、前記肺におけるＲＳＶの複製を予防する免疫応答が得られる、ＲＳＶ Ｆタンパク質。 - 前記投与が筋肉内投与である、請求項１に記載のＲＳＶ Ｆタンパク質。
- 前記哺乳動物がヒトである、請求項１または２に記載のＲＳＶ Ｆタンパク質。
- 前記哺乳動物がヒト乳児である、請求項３に記載のＲＳＶ Ｆタンパク質。
- 約１５μｇ〜約３０μｇのＲＳＶ Ｆタンパク質が投与される、請求項１に記載のＲＳＶ Ｆタンパク質。
- 前記免疫応答が中和抗体を含む、請求項１〜５のいずれか一項に記載のＲＳＶ Ｆタンパク質。
- アジュバントと共に投与される、請求項１〜６のいずれか一項に記載のＲＳＶ Ｆタンパク質。
- ＲＳＶ Ｍタンパク質、ＲＳＶ Ｎタンパク質、ＲＳＶ Ｇタンパク質およびＲＳＶ ＳＨタンパク質からなる群から選択される１つまたは複数のさらなるＲＳＶタンパク質と共にウイルス様粒子（ＶＬＰ）を形成する、請求項１〜７のいずれか一項に記載のＲＳＶ Ｆタンパク質。
- 前記不活性化した一次フューリン切断部位が、野生型ＲＳＶ Ｆタンパク質（配列番号２）のアルギニン１３３、アルギニン１３５およびアルギニン１３６からなる群から選択されるアミノ酸に対応する位置におけるアルギニンからグルタミンへのアミノ酸置換を少なくとも１つ含む、請求項１〜８のいずれか一項に記載のＲＳＶ Ｆタンパク質。
- 配列番号８のアミノ酸配列を含む、請求項１〜９のいずれか一項に記載のＲＳＶ Ｆタンパク質。
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542040P | 2011-09-30 | 2011-09-30 | |
| US61/542,040 | 2011-09-30 | ||
| US201161542721P | 2011-10-03 | 2011-10-03 | |
| US61/542,721 | 2011-10-03 | ||
| US201261611834P | 2012-03-16 | 2012-03-16 | |
| US61/611,834 | 2012-03-16 | ||
| US201261614286P | 2012-03-22 | 2012-03-22 | |
| US61/614,286 | 2012-03-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530010A JP2014530010A (ja) | 2014-11-17 |
| JP2014530010A5 true JP2014530010A5 (ja) | 2016-09-29 |
Family
ID=47996397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533316A Pending JP2014530010A (ja) | 2011-09-30 | 2012-09-27 | 呼吸器合胞体ウイルス用の組み換えナノ粒子ｒｓｖｆワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20130122032A1 (ja) |
| EP (1) | EP2760469A4 (ja) |
| JP (1) | JP2014530010A (ja) |
| KR (1) | KR20140077169A (ja) |
| CN (2) | CN104080476A (ja) |
| AU (1) | AU2013201495B2 (ja) |
| BR (1) | BR112014007616A2 (ja) |
| CA (1) | CA2849471A1 (ja) |
| HK (1) | HK1222125A1 (ja) |
| IL (1) | IL231637A0 (ja) |
| MX (1) | MX2014003777A (ja) |
| RU (1) | RU2014117068A (ja) |
| SG (2) | SG10201602434UA (ja) |
| WO (1) | WO2013049342A1 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2370099T3 (en) | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| EP2983708A4 (en) * | 2013-04-08 | 2016-10-05 | Medimmune Llc | VACCINE COMPOSITION AND METHOD OF USE |
| CA2925201A1 (en) * | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
| CN105087643A (zh) * | 2014-04-16 | 2015-11-25 | 中国科学院上海巴斯德研究所 | 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统 |
| WO2015195961A1 (en) * | 2014-06-18 | 2015-12-23 | Georgia State University And Research Foundation, Inc. | Recombinant rsv reporter virus |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2017040387A2 (en) | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| EP3344288A1 (en) * | 2015-09-02 | 2018-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized viral class i fusion proteins |
| CN114617959A (zh) * | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| CN106547635B (zh) | 2015-09-18 | 2020-10-09 | 阿里巴巴集团控股有限公司 | 一种作业的操作重试方法和装置 |
| AU2016379097C1 (en) | 2015-12-23 | 2021-04-08 | Pfizer Inc. | RSV F protein mutants |
| CN106124767A (zh) * | 2016-05-12 | 2016-11-16 | 广州瑞辉生物科技股份有限公司 | 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法 |
| WO2018067300A1 (en) | 2016-10-03 | 2018-04-12 | University Of Massachusetts | Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv) |
| JP7149285B2 (ja) | 2017-03-15 | 2022-10-06 | ノババックス，インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 |
| WO2018187325A1 (en) | 2017-04-04 | 2018-10-11 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CN107050446B (zh) * | 2017-04-19 | 2020-08-11 | 武汉博沃生物科技有限公司 | 经修饰的季节流感-rsv联合疫苗及其制备方法 |
| US12083228B2 (en) | 2017-07-24 | 2024-09-10 | Novavax, Inc. | Methods and compositions for treating respiratory disease |
| WO2019063844A1 (en) * | 2017-09-29 | 2019-04-04 | Universiteit Antwerpen | VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS |
| AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
| BR112020019108A2 (pt) | 2018-03-19 | 2020-12-29 | Novavax, Inc. | Vacinas polivalentes de nanopartículas de influenza |
| CA3115979A1 (en) * | 2018-10-12 | 2020-04-16 | Sk Bioscience Co., Ltd. | Recombinant rsv live vaccine strain and production method therefor |
| US20210401969A1 (en) * | 2018-10-29 | 2021-12-30 | Emory University | Rsv virus-like particles and methods of use thereof |
| KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| JP7253034B2 (ja) * | 2019-02-28 | 2023-04-05 | Ｋｍバイオロジクス株式会社 | Ｒｓｖ ｆ／ｇキメラワクチン |
| CN110229219B (zh) * | 2019-06-21 | 2021-03-30 | 中国科学院武汉病毒研究所 | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 |
| TW202142555A (zh) * | 2020-01-27 | 2021-11-16 | 美商諾瓦瓦克斯股份有限公司 | 冠狀病毒疫苗配製品 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN113855796B (zh) * | 2021-07-30 | 2024-01-26 | 河北医科大学 | 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用 |
| CN118434756A (zh) * | 2021-11-19 | 2024-08-02 | 达冕生物有限公司 | 核糖核酸呼吸道合胞病毒（rsv）疫苗的组合物和方法 |
| WO2024050015A1 (en) * | 2022-09-01 | 2024-03-07 | Novavax, Inc. | Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110097971A (ko) * | 2003-04-25 | 2011-08-31 | 메디뮨 백신즈, 인코포레이티드 | 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합 파라인플루엔자 바이러스 발현 시스템 및 백신 |
| WO2008114149A2 (en) * | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
| EP2176427A4 (en) * | 2007-07-19 | 2011-10-05 | Novavax Inc | VIRAL PESUDO-PARTICLES OF THE CHIMÈRE AVIAN INFLUENZA |
| PL2222710T3 (pl) * | 2007-12-24 | 2017-01-31 | Id Biomedical Corporation Of Quebec | Rekombinowane antygeny rsv |
| CN102014873A (zh) * | 2008-02-25 | 2011-04-13 | 诺瓦瓦克斯股份有限公司 | 糖玻璃化的病毒样颗粒 |
| KR101027159B1 (ko) * | 2008-07-28 | 2011-04-05 | 뮤추얼아이피서비스(주) | 타겟 영상 검출 장치 및 그 방법 |
| DK2370099T3 (en) * | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
| WO2010077712A1 (en) * | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
-
2012
- 2012-09-27 SG SG10201602434UA patent/SG10201602434UA/en unknown
- 2012-09-27 SG SG11201400999VA patent/SG11201400999VA/en unknown
- 2012-09-27 WO PCT/US2012/057546 patent/WO2013049342A1/en active Application Filing
- 2012-09-27 RU RU2014117068/10A patent/RU2014117068A/ru not_active Application Discontinuation
- 2012-09-27 CA CA2849471A patent/CA2849471A1/en not_active Abandoned
- 2012-09-27 AU AU2013201495A patent/AU2013201495B2/en not_active Ceased
- 2012-09-27 CN CN201280059282.1A patent/CN104080476A/zh active Pending
- 2012-09-27 JP JP2014533316A patent/JP2014530010A/ja active Pending
- 2012-09-27 CN CN201510769961.3A patent/CN105381457A/zh active Pending
- 2012-09-27 MX MX2014003777A patent/MX2014003777A/es unknown
- 2012-09-27 KR KR1020147009538A patent/KR20140077169A/ko not_active Application Discontinuation
- 2012-09-27 US US13/629,107 patent/US20130122032A1/en not_active Abandoned
- 2012-09-27 EP EP12835033.7A patent/EP2760469A4/en not_active Withdrawn
- 2012-09-27 BR BR112014007616A patent/BR112014007616A2/pt active Search and Examination
-
2014
- 2014-03-20 IL IL231637A patent/IL231637A0/en unknown
-
2015
- 2015-02-27 US US14/634,162 patent/US20150335730A1/en not_active Abandoned
- 2015-02-27 US US14/634,171 patent/US20150306207A1/en not_active Abandoned
-
2016
- 2016-08-31 HK HK16110329.3A patent/HK1222125A1/zh unknown
-
2017
- 2017-02-15 US US15/433,759 patent/US20170319682A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530010A5 (ja) | ||
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| RU2014117068A (ru) | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса | |
| Hemann et al. | Protective CD8 T cell–mediated immunity against influenza a virus infection following influenza virus–like particle vaccination | |
| Boyoglu-Barnum et al. | Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice | |
| Shang et al. | Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| JP2015509707A5 (ja) | ||
| JP2013543499A5 (ja) | ||
| RU2011128371A (ru) | Модифицированные f протеины sv и способы их применения | |
| Stepanova et al. | Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes | |
| JP2014502156A5 (ja) | ||
| JP2016510983A5 (ja) | ||
| JP2015517489A5 (ja) | ||
| JP2015536134A5 (ja) | ||
| JP2016510983A (ja) | 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 | |
| JP2015524422A5 (ja) | ||
| Volpatti et al. | Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity | |
| JP2011528222A5 (ja) | ||
| JP2015506705A5 (ja) | ||
| KR20220010478A (ko) | 기도 감염의 치료 또는 예방용 서브유닛 백신 | |
| Zhang et al. | Advances in developing ACE2 derivatives against SARS-CoV-2 | |
| BR112014015390A2 (pt) | vírus da estomatite vesicular para vacinas iniciais e de reforço | |
| JP2013518052A5 (ja) | ||
| JP2015504897A5 (ja) |